RxDoctor Payments DataLook up a doctor →

Minou Tran, MD

Endocrinology, Diabetes & Metabolism · Pico Rivera, CANPI 1538137054

Payments from drug & device makers

$663,025in general payments, 2019–2025

Across 2,070 payments — averaging $320.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$241K
  • Lilly USA, LLC$169K
  • Bayer$50K
  • AstraZeneca$33K
  • Merck$33K
  • Corcept Therapeutics$31K
  • plus $107K from 47 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk391$241,022
Lilly USA, LLC482$168,928
Bayer83$49,859
AstraZeneca106$32,653
Merck70$32,609
Corcept Therapeutics95$30,601
Dexcom, Inc.105$26,487
Boehringer Ingelheim91$25,450
Ascendis Pharma Endocrinology Inc48$19,046
Xeris Pharmaceuticals, Inc.54$14,483
Amgen(2 entities)130$10,901
Johnson & Johnson15$3,474
Mannkind Corporation103$1,255
Sanofi-aventis U.S. LLC37$729
AbbVie25$621
Insulet Corporation39$614
Medtronic(2 entities)24$501
Amarin Pharma, Inc.20$376
Kowa Pharmaceuticals America, Inc.29$369
Novartis14$305
Abbott14$252
BD9$217
Echosens North America, Inc.2$204
Tandem Diabetes Care, Inc.10$202
Madrigal Pharmaceuticals3$202
Cequr Corporation4$199
Radius Health, Inc.7$194
BETA Bionics, Inc.8$158
Recordati_rare_diseases_inc.6$152
Amphastar Pharmaceuticals, Inc.7$137
Antares Pharma, Inc.4$86
Ionis Pharmaceuticals, Inc.3$73
Ascensia Diabetes Care US Inc.3$65
Neurocrine Biosciences, Inc.2$64
Acella Pharmaceuticals, LLC3$51
Amneal Pharmaceuticals LLC3$51
Takeda Pharmaceuticals U.S.A., Inc.3$42
Boston Scientific1$38
Esperion Therapeutics, Inc.2$36
Eisai Inc.2$36
Janssen Scientific Affairs, LLC1$29
Kyowa Kirin, Inc.1$29
Rhythm Pharmaceuticals, Inc.1$29
Bigfoot Biomedical Inc1$26
Sequel Med Tech, LLC1$24
Sanofi1$23
Zealand Pharma US, Inc.1$23
Theracosbio, LLC1$22
Tolmar, Inc.1$20
Valeritas, Inc.1$18
Vivus LLC1$17
Intra-sana Laboratories1$16
Shire North American Group Inc1$11

How this compares

$663,025 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California →

Medicare billing

Part B allowed, 2024
$119,822
Medicare patients
293
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Pico Rivera

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →